IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs
IGC Pharma (NYSE American:IGC) has announced the addition of three industry leaders to its Board of Advisors to support its Alzheimer's drug development and AI-driven early dementia detection programs.
The new advisory board members include: Frank Zaccanelli, former President of Dallas Mavericks, who will focus on strategic partnerships and brand ambassador engagement; Robert K. Coughlin, former MassBio CEO and recipient of the 2025 Henri A. Termeer Innovative Leadership Award, who will support regulatory strategy and pharmaceutical relations; and Joseph H. Mangan, a retired brand strategist, who will advise on partnerships with clinical sites, hospitals, and Alzheimer's foundations.
IGC Pharma (NYSE American:IGC) ha annunciato l'ingresso di tre leader del settore nel suo Consiglio di Consulenti per supportare lo sviluppo di farmaci per l'Alzheimer e i programmi di rilevamento precoce della demenza basati sull'intelligenza artificiale.
I nuovi membri del consiglio consultivo sono: Frank Zaccanelli, ex Presidente dei Dallas Mavericks, che si concentrerà sulle partnership strategiche e sull'engagement come ambasciatore del marchio; Robert K. Coughlin, ex CEO di MassBio e vincitore del Premio Henri A. Termeer per la Leadership Innovativa 2025, che sosterrà la strategia regolatoria e i rapporti con l'industria farmaceutica; e Joseph H. Mangan, stratega di brand in pensione, che consiglierà sulle collaborazioni con centri clinici, ospedali e fondazioni per l'Alzheimer.
IGC Pharma (NYSE American:IGC) ha anunciado la incorporación de tres líderes del sector a su Consejo Asesor para apoyar el desarrollo de su medicamento para el Alzheimer y los programas de detección temprana de demencia impulsados por inteligencia artificial.
Los nuevos miembros del consejo asesor incluyen a: Frank Zaccanelli, ex Presidente de los Dallas Mavericks, quien se enfocará en alianzas estratégicas y en la participación como embajador de la marca; Robert K. Coughlin, ex CEO de MassBio y galardonado con el Premio a la Liderazgo Innovador Henri A. Termeer 2025, quien apoyará la estrategia regulatoria y las relaciones farmacéuticas; y Joseph H. Mangan, estratega de marca retirado, que asesorará en asociaciones con centros clínicos, hospitales y fundaciones contra el Alzheimer.
IGC Pharma (NYSE American:IGC)는 알츠하이머 약물 개발과 AI 기반 초기 치매 감지 프로그램을 지원하기 위해 업계 리더 세 명을 자문위원회에 추가했다고 발표했습니다.
새 자문위원회 멤버는 다음과 같습니다: Frank Zaccanelli, 전 댈러스 매버릭스 회장으로 전략적 파트너십 및 브랜드 홍보 대사 역할을 맡을 예정이며; Robert K. Coughlin, 전 MassBio CEO이자 2025년 Henri A. Termeer 혁신 리더십 상 수상자로서 규제 전략 및 제약 관계를 지원할 것입니다; 그리고 Joseph H. Mangan, 은퇴한 브랜드 전략가로 임상 기관, 병원, 알츠하이머 재단과의 파트너십에 대해 자문할 예정입니다.
IGC Pharma (NYSE American:IGC) a annoncé l'ajout de trois leaders du secteur à son Conseil consultatif afin de soutenir le développement de son médicament contre la maladie d'Alzheimer et ses programmes de détection précoce de la démence basés sur l'intelligence artificielle.
Les nouveaux membres du conseil consultatif sont : Frank Zaccanelli, ancien président des Dallas Mavericks, qui se concentrera sur les partenariats stratégiques et l'engagement en tant qu'ambassadeur de la marque ; Robert K. Coughlin, ancien PDG de MassBio et récipiendaire du prix Henri A. Termeer pour le leadership innovant 2025, qui soutiendra la stratégie réglementaire et les relations pharmaceutiques ; et Joseph H. Mangan, stratège de marque à la retraite, qui conseillera sur les partenariats avec les sites cliniques, les hôpitaux et les fondations Alzheimer.
IGC Pharma (NYSE American:IGC) hat die Aufnahme von drei Branchenführern in seinen Beirat bekannt gegeben, um die Entwicklung von Alzheimer-Medikamenten und KI-gestützte Programme zur Früherkennung von Demenz zu unterstützen.
Die neuen Beiratsmitglieder sind: Frank Zaccanelli, ehemaliger Präsident der Dallas Mavericks, der sich auf strategische Partnerschaften und Markenbotschafter-Engagement konzentrieren wird; Robert K. Coughlin, ehemaliger CEO von MassBio und Empfänger des Henri A. Termeer Innovative Leadership Award 2025, der die regulatorische Strategie und pharmazeutische Beziehungen unterstützt; sowie Joseph H. Mangan, ein pensionierter Markenstratege, der zu Partnerschaften mit klinischen Einrichtungen, Krankenhäusern und Alzheimer-Stiftungen berät.
- Strategic expansion of advisory board with experienced industry leaders
- Enhanced expertise in regulatory strategy and pharmaceutical relations
- Strengthened capabilities in strategic partnerships and brand development
- None.
Industry Veterans Bring Deep Strategic Experience to Guide Alzheimer's Clinical Expansion and Commercial Strategy
POTOMAC, MARYLAND / ACCESS Newswire / April 21, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the addition of Frank Zaccanelli, Robert K. Coughlin, and Joseph Mangan to its Board of Advisors. The Advisory Board will provide strategic guidance as IGC advances its Alzheimer's drug development and AI driven early dementia detection programs.
Frank Zaccanelli, a seasoned entrepreneur and former President, General Manager, and minority owner of the Dallas Mavericks, under Perot family's majority ownership. He led the development of the American Airlines Center in Dallas Texas and has been a public commentator on finance, politics, global strategy, and brings decades of leadership in venture capital, private equity, and public-private partnerships. Mr. Zaccanelli will support IGC Pharma in identifying and cultivating strategic partnerships, as well as advising on the Company's engagement with brand ambassador and key influencers in the Alzheimer's space.
Robert K. Coughlin, former President and CEO of MassBio, has been a champion of biotech innovation and recently received the 2025 Henri A. Termeer Innovative Leadership Award for his enduring contributions to the life sciences ecosystem. As a cystic fibrosis parent, Bob works tirelessly to raise awareness and invest in companies working on cystic fibrosis. His public service includes time as a Massachusetts State Representative and Undersecretary of Economic Development. Mr. Coughlin will support IGC's Alzheimer's regulatory strategy, clinical engagement, and support relations with pharmaceutical companies.
Joseph H. Mangan is a retired brand strategist, a current Knight of the Order of Malta, and a board member of the New York Athletic Club. Joe has been committed to humanitarian aid and service to those in need. His deep empathy for vulnerable populations, particularly the elderly, aligns closely with IGC Pharma's mission to support Alzheimer's patients and caregivers. Mr. Mangan will advise the Company on strategic partnerships with clinical sites, hospitals, and Alzheimer's foundations.
"We warmly welcome our new members to the Advisory Board and look forward to working together as we advance our Alzheimer's clinical strategy and AI driven early dementia detection programs," said Ram Mukunda, CEO of IGC Pharma. "Their diverse expertise across biotechnology, brand strategy, and business development adds meaningful depth to our leadership as we advance our Alzheimer's clinical and AI programs. With their guidance, we are better positioned to scale responsibly, accelerate our mission, and deliver sustained value to both patients and shareholders."
About IGC Pharma (dba IGC):
IGC Pharma (NYSE American: IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With 30 patent filings and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.
Forward-Looking Statements:
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 24, 2024, and on Form 10-Qs filed with the SEC on August 7, 2024, November 12, 2024, and February 14, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
Contact Information
Rosalyn Christian
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200
SOURCE: IGC Pharma, Inc.
View the original press release on ACCESS Newswire
FAQ
What strategic appointments did IGC Pharma make to advance its Alzheimer's programs in April 2025?
How will Robert K. Coughlin contribute to IGC Pharma's Alzheimer's initiatives?
What is Frank Zaccanelli's role in IGC Pharma's advisory board?
What are IGC Pharma's main development programs in 2025?
